| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bo Pang, Lu-Lu Zhang, Bin Li, Feng-Xian Sun, Zhi-Da Wan. The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. Physiology & behavior. 2023-02-22. PMID:36809844. |
an antidiabetic agent sodium glucose co-transporter 2 (sglt2) inhibitor ertugliflozin has been revealed to bind to catalytic anionic site of acetylcholinesterase (ache), which is considered to be associated with the cognitive decline in neurodegenerative diseases, such as alzheimer's disease (ad). |
2023-02-22 |
2023-08-14 |
rat |
| Hongjie Qian, Chengyin Yu, Huijuan Zhu, Qichen Ding, Yuting Cai, Jiao Jing, Xin Xu, Runcong Guo, Haiyan Zhang, Hong Liu, Xiaoyan Chen, Yun Li. Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel AChE inhibitor: A phase I study in healthy young and elderly Chinese subjects. Clinical and translational science. 2023-02-17. PMID:36798012. |
the present study evaluated the safety, tolerability, and pharmacokinetics of fluoropezil (dc20), a novel ache inhibitor under development for the treatment of alzheimer's disease (ad) in otherwise healthy young and elderly chinese subjects. |
2023-02-17 |
2023-08-14 |
human |
| Luciane B Silva, Elenilze F B Ferreira, Maryam, José M Espejo-Román, Glauber V Costa, Josiane V Cruz, Njogu M Kimani, Josivan S Costa, José A H M Bittencourt, Jorddy N Cruz, Joaquín M Campos, Cleydson B R Santo. Galantamine Based Novel Acetylcholinesterase Enzyme Inhibitors: A Molecular Modeling Design Approach. Molecules (Basel, Switzerland). vol 28. issue 3. 2023-02-11. PMID:36770702. |
acetylcholinesterase (ache) enzymes play an essential role in the development of alzheimer's disease (ad). |
2023-02-11 |
2023-08-14 |
Not clear |
| Ankita Rajput, Palvi Sharma, Nitish Kumar, Sarabjit Kaur, Saroj Aror. Neuroprotective activity of novel phenanthrene derivative from Grewia tiliaefolia by in vitro and in silico studies. Scientific reports. vol 13. issue 1. 2023-02-10. PMID:36765125. |
in silico study was conducted to predict its action on proteins playing crucial role in neurological and neurodegenerative disorders such as gamma amino butyric acid (gaba) receptor and glutamate α amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid (glu ampa) receptor in epilepsy and ache enzyme in alzheimer's diseases. |
2023-02-10 |
2023-08-14 |
Not clear |
| Ankita Rajput, Palvi Sharma, Nitish Kumar, Sarabjit Kaur, Saroj Aror. Neuroprotective activity of novel phenanthrene derivative from Grewia tiliaefolia by in vitro and in silico studies. Scientific reports. vol 13. issue 1. 2023-02-10. PMID:36765125. |
further, molecular dynamic simulations and adme studies of a-1 and ache enzyme revealed that a-1 yielded good results in all parameters and hence can relieve alzheimer's like symptoms. |
2023-02-10 |
2023-08-14 |
Not clear |
| Fang Wang, Mingxue Liu, Xiankang Niu, Lian Xia, Fengli Q. Dextran-assisted ultrasonic exfoliation of two-dimensional metal-organic frameworks to evaluate acetylcholinesterase activity and inhibitor screening. Analytica chimica acta. vol 1243. 2023-01-25. PMID:36697184. |
acetylcholinesterase (ache) is regarded as a biomarker of alzheimer's disease (ad), and its inhibitors show great potential in ad therapy as ache can increase the neurotoxicity of the amyloid component that induces ad. |
2023-01-25 |
2023-08-14 |
Not clear |
| María-Ángeles Cortés-Gómez, Víctor M Barberá, Jordi Alom, Javier Sáez-Valero, María-Salud García-Aylló. Presenilin 1 Modulates Acetylcholinesterase Trafficking and Maturation. International journal of molecular sciences. vol 24. issue 2. 2023-01-21. PMID:36674948. |
in alzheimer's disease (ad), the reduction in acetylcholinesterase (ache) enzymatic activity is not paralleled with changes in its protein levels, suggesting the presence of a considerable enzymatically inactive pool in the brain. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ignazio Schino, Mariangela Cantore, Modesto de Candia, Cosimo D Altomare, Catarina Maria, João Barros, Vasco Cachatra, Patrícia Calado, Karina Shimizu, Adilson A Freitas, Maria C Oliveira, Maria J Ferreira, José N C Lopes, Nicola A Colabufo, Amélia P Raute. Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer's Disease. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678552. |
alzheimer's disease (ad) is characterized by a progressive cholinergic neurotransmission imbalance, with a decrease of acetylcholinesterase (ache) activity followed by a significant increase of butyrylcholinesterase (bche) in the later ad stages. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ashraf K El-Damasy, Jong Eun Park, Hyun Ji Kim, Jinhyuk Lee, Eun-Kyoung Bang, Hoon Kim, Gyochang Keu. Identification of New Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678580. |
identification of new monoamine oxidase-b (mao-b), acetylcholinesterase (ache), and butyrylcholinesterase (bche) have been considered target enzymes of depression and neurodegenerative diseases, including alzheimer's disease (ad). |
2023-01-21 |
2023-08-14 |
Not clear |
| Raquel B M de Almeida, Deyse B Barbosa, Mayra R do Bomfim, Jéssika A O Amparo, Bruno S Andrade, Silvia L Costa, Joaquín M Campos, Jorddy N Cruz, Cleydson B R Santos, Franco H A Leite, Mariana B Botur. Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies. Pharmaceuticals (Basel, Switzerland). vol 16. issue 1. 2023-01-21. PMID:36678592. |
the enhancement of cholinergic functions via acetylcholinesterase (ache) and butyrylcholinesterase (buche) inhibition is considered a valuable therapeutic strategy for the treatment of alzheimer's disease. |
2023-01-21 |
2023-08-14 |
Not clear |
| Shraddha Manish Gupta, Ashok Behera, Neetesh K Jain, Devendra Kumar, Avanish Tripathi, Shailesh Mani Tripathi, Somdutt Mujwar, Jeevan Patra, Arvind Neg. Indene-Derived Hydrazides Targeting Acetylcholinesterase Enzyme in Alzheimer's: Design, Synthesis, and Biological Evaluation. Pharmaceutics. vol 15. issue 1. 2023-01-21. PMID:36678724. |
as acetylcholinesterase (ache) plays a crucial role in advancing alzheimer's disease (ad), its inhibition is a promising approach for treating ad. |
2023-01-21 |
2023-08-14 |
Not clear |
| Maram B Alhawarri, Roza Dianita, Mira Syahfriena Amir Rawa, Toshihiko Nogawa, Habibah A Waha. Potential Anti-Cholinesterase Activity of Bioactive Compounds Extracted from Plants (Basel, Switzerland). vol 12. issue 2. 2023-01-21. PMID:36679057. |
potential anti-cholinesterase activity of bioactive compounds extracted from acetylcholinesterase (ache) inhibitors remain the primary therapeutic drug that can alleviate alzheimer's disease's (ad) symptoms. |
2023-01-21 |
2023-08-14 |
Not clear |
| Ce Zhang, Mingan Li, Wei Xie, Min Li, Chunna You, Tian Wang, Fenghua F. Administration of Huperzine a microspheres ameliorates myocardial ischemic injury via α7nAChR-dependent JAK2/STAT3 signaling pathway. European journal of pharmacology. 2022-12-23. PMID:36563953. |
acetylcholinesterase (ache) inhibitor (achei) is well established as first-line agents for relieving the symptoms of alzheimer's disease (ad). |
2022-12-23 |
2023-08-14 |
mouse |
| Rebecca Lustosa Silva de Almeida Luz, Raquel B M Almeida, Mara Márcia Sampaio Albuquerque, Amanda Ponce Morais Cerqueira, Josean Fechine, Marcelo Sobral da Silva, Raimundo Braz Filho, Manoelito C Dos Santos Junior, Alexsandro Branco, Mariana B Botur. Two new dilactonized glycerol glycosides of the dual anticholinesterase active extract from Ocotea daphnifolia using bioguided fractionation and molecular docking studies. Chemical biology & drug design. 2022-12-17. PMID:36527177. |
the dual inhibition of acetylcholinesterase (ache) and butyrylcholinesterase (buche) is considered as an important strategy for the treatment of alzheimer's disease. |
2022-12-17 |
2023-08-14 |
Not clear |
| Ashish Patel, Drashti Shah, Yug Patel, Stuti Patel, Meshwa Mehta, Tushar Bambharoliy. A Review on Recent Development of Novel Heterocycles as Acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Current drug targets. 2022-12-14. PMID:36515018. |
acetylcholinesterase (ache) has obtained a renewed interest as a therapeutic target in alzheimer's disease (ad) due to increased neural cells' function by increasing the concentration of acetylcholine. |
2022-12-14 |
2023-08-14 |
Not clear |
| Ashish Patel, Drashti Shah, Yug Patel, Stuti Patel, Meshwa Mehta, Tushar Bambharoliy. A Review on Recent Development of Novel Heterocycles as Acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Current drug targets. 2022-12-14. PMID:36515018. |
as ache inhibitors for the treatment of alzheimer disease. |
2022-12-14 |
2023-08-14 |
Not clear |
| Ashish Patel, Drashti Shah, Yug Patel, Stuti Patel, Meshwa Mehta, Tushar Bambharoliy. A Review on Recent Development of Novel Heterocycles as Acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Current drug targets. 2022-12-14. PMID:36515018. |
the results suggest that all the compounds constitute promising leads for the ache targeted approach for alzheimer's disease. |
2022-12-14 |
2023-08-14 |
Not clear |
| Natália Chermont Dos Santos Moreira, Elvira Regina Tamarozzi, Jessica Ellen Barbosa de Freitas Lima, Larissa de Oliveira Piassi, Ivone Carvalho, Geraldo Aleixo Passos, Elza Tiemi Sakamoto-Hoj. Novel Dual AChE and ROCK2 Inhibitor Induces Neurogenesis via PTEN/AKT Pathway in Alzheimer's Disease Model. International journal of molecular sciences. vol 23. issue 23. 2022-12-11. PMID:36499116. |
novel dual ache and rock2 inhibitor induces neurogenesis via pten/akt pathway in alzheimer's disease model. |
2022-12-11 |
2023-08-14 |
Not clear |
| Ye-Piao Yan, Jia-Yue Chen, Jia-Hong L. Disease-Modifying Activity of Huperzine A on Alzheimer's Disease: Evidence from Preclinical Studies on Rodent Models. International journal of molecular sciences. vol 23. issue 23. 2022-12-11. PMID:36499562. |
(1) background: huperzine a, a natural cholinesterase (ache) inhibitor isolated from the chinese herb huperzia serrata, has been used as a dietary supplement in the united states and a drug in china for therapeutic intervention on alzheimer's disease (ad). |
2022-12-11 |
2023-08-14 |
Not clear |
| Noa Stern, Alexandra Gacs, Enikő Tátrai, Beáta Flachner, István Hajdú, Krisztina Dobi, István Bágyi, György Dormán, Zsolt Lőrincz, Sándor Cseh, Attila Kígyós, József Tóvári, Amiram Goldblu. Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer's Disease: From In Silico to In Vivo. International journal of molecular sciences. vol 23. issue 21. 2022-11-11. PMID:36361906. |
dual inhibitors of ache and bace-1 for reducing aβ in alzheimer's disease: from in silico to in vivo. |
2022-11-11 |
2023-08-14 |
Not clear |